Amphastar Pharmaceuticals (AMPH) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to -$276.2 million.
- Amphastar Pharmaceuticals' Enterprise Value fell 1026.7% to -$276.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$276.2 million, marking a year-over-year decrease of 1026.7%. This contributed to the annual value of -$221.6 million for FY2024, which is 1369.17% up from last year.
- Amphastar Pharmaceuticals' Enterprise Value amounted to -$276.2 million in Q3 2025, which was down 1026.7% from -$231.8 million recorded in Q2 2025.
- In the past 5 years, Amphastar Pharmaceuticals' Enterprise Value ranged from a high of -$69.7 million in Q1 2021 and a low of -$299.9 million during Q3 2023
- Its 5-year average for Enterprise Value is -$198.3 million, with a median of -$192.9 million in 2023.
- Per our database at Business Quant, Amphastar Pharmaceuticals' Enterprise Value crashed by 20246.38% in 2021 and then surged by 1819.07% in 2025.
- Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Enterprise Value stood at -$136.7 million in 2021, then fell by 28.6% to -$175.8 million in 2022, then crashed by 46.11% to -$256.8 million in 2023, then increased by 13.69% to -$221.6 million in 2024, then dropped by 24.62% to -$276.2 million in 2025.
- Its Enterprise Value stands at -$276.2 million for Q3 2025, versus -$231.8 million for Q2 2025 and -$236.9 million for Q1 2025.